178 related articles for article (PubMed ID: 30880443)
1. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program.
Shavadia JS; Sharma A; Gu X; Neaton J; DeLeve L; Holmes D; Home P; Eckel RH; Watkins PB; Granger CB
Clin Trials; 2019 Jun; 16(3):253-262. PubMed ID: 30880443
[TBL] [Abstract][Full Text] [Related]
2. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
[TBL] [Abstract][Full Text] [Related]
3. Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial.
Menon V; Lincoff AM; Nicholls SJ; Jasper S; Wolski K; McGuire DK; Mehta CR; Rosenstock J; Lopez C; Marcinak J; Cao C; Nissen SE;
Diabetes Care; 2018 Dec; 41(12):2603-2609. PubMed ID: 30459247
[TBL] [Abstract][Full Text] [Related]
4. Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.
Marcinak J; Cao C; Lee D; Ye Z
Diabetes Obes Metab; 2017 Dec; 19(12):1714-1721. PubMed ID: 28493502
[TBL] [Abstract][Full Text] [Related]
5. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Peng XV; Marcinak JF; Raanan MG; Cao C
Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
[TBL] [Abstract][Full Text] [Related]
6. Fasiglifam as a new potential treatment option for patients with type 2 diabetes.
Kaku K
Expert Opin Pharmacother; 2013 Dec; 14(18):2591-600. PubMed ID: 24195772
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Fasiglifam-Related Liver Toxicity in Dogs.
Kogame A; Moriya Y; Mori I; Pan L; Morohashi A; Ebihara T; Fukui H; Tagawa Y; Benet LZ
Drug Metab Dispos; 2019 May; 47(5):525-534. PubMed ID: 30765394
[TBL] [Abstract][Full Text] [Related]
8. A thorough QT/QTc study of the effect of fasiglifam, a GPR40 agonist, on cardiac repolarization in healthy adults.
Lee RD; Nudurupati S; Marcinak J; Viswanathan P
Clin Pharmacol Drug Dev; 2015; 4(3):175-83. PubMed ID: 27140797
[TBL] [Abstract][Full Text] [Related]
9. Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.
Lin X; Parks D; Painter J; Hunt CM; Stirnadel-Farrant HA; Cheng J; Menius A; Lee K
Drug Saf; 2012 Oct; 35(10):865-75. PubMed ID: 22928730
[TBL] [Abstract][Full Text] [Related]
10. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
Watkins PB; Lewis JH; Kaplowitz N; Alpers DH; Blais JD; Smotzer DM; Krasa H; Ouyang J; Torres VE; Czerwiec FS; Zimmer CA
Drug Saf; 2015 Nov; 38(11):1103-13. PubMed ID: 26188764
[TBL] [Abstract][Full Text] [Related]
11. A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.
Parks D; Lin X; Painter JL; Cheng J; Hunt CM; Spraggs CF; Nelson JJ; Curtis L; Menius JA; Lee KR
Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):571-8. PubMed ID: 23300062
[TBL] [Abstract][Full Text] [Related]
12. In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials.
Church RJ; Watkins PB
Exp Biol Med (Maywood); 2018 Feb; 243(3):300-307. PubMed ID: 29096561
[TBL] [Abstract][Full Text] [Related]
13. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.
Genovese MC; Kremer JM; van Vollenhoven RF; Alten R; Scali JJ; Kelman A; Dimonaco S; Brockwell L
Arthritis Rheumatol; 2017 Sep; 69(9):1751-1761. PubMed ID: 28597609
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
Ailani J; Lipton RB; Hutchinson S; Knievel K; Lu K; Butler M; Yu SY; Finnegan M; Severt L; Trugman JM
Headache; 2020 Jan; 60(1):141-152. PubMed ID: 31913519
[TBL] [Abstract][Full Text] [Related]
15. Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law.
Shen X; Yuan Z; Mei J; Zhang Z; Guo J; Wu Z; Wu J; Zhang H; Pan J; Huang W; Gong H; Yuan D; Xiao P; Wang Y; Shuai Y; Lin S; Pan Q; Zhou T; Watkins PB; Wu F
Drug Saf; 2014 Jan; 37(1):43-51. PubMed ID: 24203912
[TBL] [Abstract][Full Text] [Related]
16. Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies.
Laurenza A; Yang H; Williams B; Zhou S; Ferry J
Epilepsy Res; 2015 Jul; 113():76-85. PubMed ID: 25986193
[TBL] [Abstract][Full Text] [Related]
17. Drug-Induced Liver Injury Is a Major Risk for New Drugs.
Seeff LB
Dig Dis; 2015; 33(4):458-63. PubMed ID: 26159259
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment.
Marcinak J; Vakilynejad M; Kogame A; Tagawa Y
Drugs R D; 2018 Jun; 18(2):109-118. PubMed ID: 29488154
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
Lebovitz HE; Kreider M; Freed MI
Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
[TBL] [Abstract][Full Text] [Related]
20. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.
Francis GS; Grumser Y; Alteri E; Micaleff A; O'Brien F; Alsop J; Stam Moraga M; Kaplowitz N
Drug Saf; 2003; 26(11):815-27. PubMed ID: 12908850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
